Breaking News Instant updates and real-time market news.

EMS

Emergency Medical

, CLCD

CoLucid Pharmaceuticals

$36.26

-0.7 (-1.89%)

08:30
10/07/16
10/07
08:30
10/07/16
08:30

Five new option listings and four option delistings on October 7th

New option listings for October 7th include FTSE Emerging Index Settlement Value (.EMS), CoLucid Pharmaceuticals (CLCD), Donnelley Financial Solutions Inc (DFIN), LSC Communications Inc (LKSD), and Silver Run Acquisition Corp (SRAQ). Option delistings effective October 7th include FTSE Emerging Index (.FTEM), Hutchinson Technolgy Incorporated (HTCH), Parkway Properties Inc (PKY), and Warren Resources Inc (WRESQ).

EMS

Emergency Medical

CLCD

CoLucid Pharmaceuticals

$36.26

-0.7 (-1.89%)

DFIN

Donnelley Financial Solutions

$21.87

0.02 (0.09%)

LKSD

LSC Communications

$26.89

-0.19 (-0.70%)

HTCH

Hutchinson Technology

PKY

Parkway

  • 10

    Nov

EMS Emergency Medical

CLCD CoLucid Pharmaceuticals
$36.26

-0.7 (-1.89%)

09/06/16
LTCO
09/06/16
NO CHANGE
Target $52
LTCO
Buy
CoLucid price target raised to $52 from $23 at Ladenburg
Ladenburg raised CoLucid's price target to $52 from $23 following achievement of both primary and key secondary endpoints in the SAMURAI Phase III pivotal trial of Lasmiditan in migraine.
09/06/16
WBLR
09/06/16
NO CHANGE
Target $30
WBLR
Outperform
CoLucid price target raised to $30 from $22 at William Blair
William Blair analyst Tim Lugo raised his price target for CoLucid Pharmaceuticals to $30 after the company announced positive results from its first pivotal Phase III trial with lead candidate lasmiditan for the treatment of acute migraine. The data "remove a major clinical overhang" for the shares since the trial endpoints were established in line with the FDA's draft guidance for acute migraine therapies, Lugo tells investors in a research note. He keeps an Outperform rating on the shares. CoLucid is up 78% to $19.00 in pre-market trading.
09/15/16
PIPR
09/15/16
NO CHANGE
Target $36
PIPR
Overweight
CoLucid price target raised to $36 from $21 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for CoLucid Pharmaceuticals to $36 saying the positive Phase III results from lasmiditan de-risk further development of the "novel mechanism" in acute migraine. The analyst reiterates an Overweight rating on the shares.
09/19/16
LTCO
09/19/16
NO CHANGE
Target $57
LTCO
Buy
CoLucid could have takeout potential following lasmiditan data, says Ladenburg
After CoLucid presented additional detail on its Phase 3 pivotal trial evaluating lasmiditan, the "SAMURAI" study, Ladenburg Thalmann analyst Robert Hazlett said the additional details support the drug's efficacy in the treatment of acute migraine. Hazlett now includes the potential for a takeover in his valuation of the stock, explaining that he values CoLucid at $45.71 per share as a stand-alone entity and values it at $68.13 per share using a takeover scenario, arriving at a raised $57 price target, up from his prior target of $52. Hazlett maintains a Buy rating on CoLucid shares, which are up about 4% to $29.19 in pre-market trading.
DFIN Donnelley Financial Solutions
$21.87

0.02 (0.09%)

LKSD LSC Communications
$26.89

-0.19 (-0.70%)

HTCH Hutchinson Technology

PKY Parkway

08/17/16
BARD
08/17/16
DOWNGRADE
Target $18
BARD
Neutral
Parkway Properties downgraded to Neutral at Baird
As reported previously, Baird analyst David Rodgers downgraded Parkway Properties to Neutral from Outperform as he expects market rates to decline and the less attractiveness of the companies assets relative to peers. Rodgers lowered his price target to $18 from $19 on Parkway Properties shares.
08/31/16
RAJA
08/31/16
DOWNGRADE
RAJA
Market Perform
Parkway Properties downgraded to Market Perform at Raymond James
Raymond James analyst William Crow downgraded Parkway Properties (PKY) to Market Perform from Outperform citing the upcoming merger with Cousins Properties (CUZ).
09/28/16
STFL
09/28/16
DOWNGRADE
STFL
Sell
Parkway Properties downgraded to Sell from Hold at Stifel
09/29/16
STFL
09/29/16
DOWNGRADE
STFL
Sell
Parkway Properties downgraded based on valuation at Stifel
As noted earlier, Stifel downgraded Parkway Properties (PKW) to Sell from Hold. Analyst John Guinee downgraded the stock based on valuation. .Additionally, he notes that Parkway and Cousins (CUZ) have agreed to merge and then spin off Houston-based assets. The analyst thinks that investors will lack information about various aspects of the combined company in the wake of the spin off announcement. Parkway target to $15.50 from $18.50.

TODAY'S FREE FLY STORIES

BDX

Becton Dickinson

$231.37

2.83 (1.24%)

08:56
01/18/18
01/18
08:56
01/18/18
08:56
Hot Stocks
Becton Dickinson says enrollment complete in Lutonix below-the-knee trial »

BD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

SCHW

Charles Schwab

$56.09

0.56 (1.01%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Recommendations
Charles Schwab analyst commentary  »

Charles Schwab price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.18

-0.06 (-0.19%)

, GE

General Electric

$17.35

-0.86 (-4.72%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Options
Notable open interest changes for January 18th »

Wednesday's total…

BAC

Bank of America

$31.18

-0.06 (-0.19%)

GE

General Electric

$17.35

-0.86 (-4.72%)

FB

Facebook

$177.60

-0.79 (-0.44%)

BABA

Alibaba

$183.83

1.43 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 07

    Feb

  • 15

    Feb

  • 28

    Feb

08:55
01/18/18
01/18
08:55
01/18/18
08:55
General news
U.S. housing starts dropped 8.2% to 1.192 M in December »

U.S. housing starts…

ABM

ABM

$38.73

0.26 (0.68%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
ABM to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

, AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
Antero Resources to host analyst day »

Analyst Day to be held in…

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

AR

Antero Resources

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

BIVV

Bioverativ

$62.32

-1.55 (-2.43%)

08:54
01/18/18
01/18
08:54
01/18/18
08:54
Initiation
Bioverativ initiated  »

Bioverativ assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 25

    Apr

UTHR

United Therapeutics

$140.32

5.2 (3.85%)

08:54
01/18/18
01/18
08:54
01/18/18
08:54
Initiation
United Therapeutics initiated  »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$82.47

2.05 (2.55%)

08:53
01/18/18
01/18
08:53
01/18/18
08:53
Recommendations
PayPal analyst commentary  »

PayPal Q4 may see upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

EDGE

Edge Therapeutics

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Initiation
Edge Therapeutics initiated  »

Edge Therapeutics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$90.14

1.79 (2.03%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

SNAP

Snap

$13.52

0.02 (0.15%)

, FB

Facebook

$177.60

-0.79 (-0.44%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Conference/Events
SunTrust Internet & digital media analyst holds analyst/industry conference call »

Internet & Digital…

SNAP

Snap

$13.52

0.02 (0.15%)

FB

Facebook

$177.60

-0.79 (-0.44%)

GOOG

Alphabet

$1,131.98

10.22 (0.91%)

GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

TWTR

Twitter

$24.56

-0.1 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

BMRN

BioMarin

$89.64

-0.6 (-0.66%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Initiation
BioMarin initiated  »

BioMarin assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 25

    May

LEN

Lennar

$70.71

1.93 (2.81%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Upgrade
Lennar rating change  »

Lennar upgraded to Buy at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICBK

County Bancorp

$30.73

-1.57 (-4.86%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Earnings
County Bancorp reports Q4 EPS 30c, consensus 47c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$34.40

0.64 (1.90%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Upgrade
PulteGroup rating change  »

PulteGroup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AVXS

AveXis

$104.87

-0.14 (-0.13%)

08:50
01/18/18
01/18
08:50
01/18/18
08:50
Initiation
AveXis initiated  »

AveXis initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MS

Morgan Stanley

$55.35

0.75 (1.37%)

08:50
01/18/18
01/18
08:50
01/18/18
08:50
Hot Stocks
Morgan Stanley CEO sees immediate positive impact from tax reform »

Sees meaningful reduction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

08:50
01/18/18
01/18
08:50
01/18/18
08:50
General news
U.S. Philly Fed's manufacturing index fell 5.7 points to 22.2 in January »

U.S. Philly Fed's…

IIPR

Innovative Industrial Properties

$31.30

-2.49 (-7.37%)

08:49
01/18/18
01/18
08:49
01/18/18
08:49
Syndicate
Innovative Industrial Properties 2.8M share Spot Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MYOK

MyoKardia

$52.60

0.6 (1.15%)

08:49
01/18/18
01/18
08:49
01/18/18
08:49
Initiation
MyoKardia initiated  »

MyoKardia assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$47.77

1.96 (4.28%)

08:49
01/18/18
01/18
08:49
01/18/18
08:49
Initiation
Ultragenyx initiated  »

Ultragenyx initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

GSL

Global Ship Lease

$1.16

-0.05 (-4.13%)

08:48
01/18/18
01/18
08:48
01/18/18
08:48
Hot Stocks
Global Ship Lease engages Evercore to explore strategic alternatives »

Global Ship Lease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRML

Vermillion

$1.67

-0.04 (-2.34%)

08:48
01/18/18
01/18
08:48
01/18/18
08:48
Hot Stocks
Vermillion signs agreement for OVA1 test with BlueCross BlueShield of Illinois »

Vermillion company ASPiRA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$51.53

0.21 (0.41%)

08:47
01/18/18
01/18
08:47
01/18/18
08:47
Initiation
Spark Therapeutics initiated  »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.